upadacitinib sold brand name rinvoq medication used treatment rheumatoid arthritis psoriatic arthritis atopic dermatitis ulcerative colitis crohns disease ankylosing spondylitis axial upadacitinib janus kinase jak inhibitor works blocking action enzymes called janus enzymes involved setting processes lead inflammation blocking effect brings inflammation joints common side effects include upper respiratory tract infections common cold sinus infections nausea cough upadacitinib approved medical use united states european union upadacitinib indicated treatment rheumatoid arthritis psoriatic arthritis atopic dermatitis ulcerative colitis crohns disease ankylosing spondylitis axial upadacitinib indicated treatment moderate severe active rheumatoid arthritis adults responded inadequately intolerant one diseasemodifying antirheumatic drugs upadacitinib may used monotherapy combination upadacitinib approved january fda treating adults children twelve years age older moderate severe treatment refractory atopic upadacitinib approved march fda treating adults moderately severely active ulcerative colitis respond treatment antitnf drugs eg upadacitinib approved february uk medicines healthcare products regulatory agency mhra treat adults moderately severely active crohns april upadacitinib approved eu treatment moderately severely active crohns disease may fda approved upadacitinib treatment adults moderately severely active crohns disease inadequate response intolerance one tnf drug contraindicated people active tuberculosis severe infections severe liver impairment score c substances strongly inhibit liver enzyme ketoconazole itraconazole clarithromycin increase upadacitinib concentrations body study ketoconazole increased auc conversely substances strongly induce lower upadacitinib concentrations example rifampicin reduced auc upadacitinib seems weak inducer lowers concentrations substrates enzyme midazolam auc effect substrates common side effects include upper respiratory tract infections common cold sinus infections nausea cough fever also reported cases patients experiencing weight gain rosacea janus kinases jaks family cytoplasmic tyrosine kinases whose function transduce cytokinemediated signals via jakstat pathway four jak subtypes overlapping receptor responsibilities inhibitors enzyme family jakinibs shown efficacy treating certain inflammatory autoimmune diseases rheumatoid arthritis crohns disease however first generation drugs tofacitinib ruxolitinib lacked subtype selectivity affecting respectively led doselimiting side effects otherwise promising class upadacitinib second generation janus kinase inhibitor selective subtype enzyme tyrosine kinase oral intake upadacitinib reaches highest concentrations blood plasma two four hours fatty meal clinically relevant effect resorption steadystate conditions reached four days accumulation minimal significant first pass effect bloodstream substance bound plasma proteins mainly metabolized possibly minor extent important pathway consists oxidation carboxylic acid subsequent glucuronidation yielding metabolite called however drug circulates form upadacitinib metabolites present small fractions none pharmacologically drug excreted mainly original substance found feces urine mean terminal halflife upadacitinib approved medical use united states august us food drug administration fda approved upadacitinib based evidence five clinical trials trial trial trial trial trial participants active rheumatoid arthritis trials conducted australia new zealand israel south africa asia northcentralsouth america five trials established benefits side effects trials enrolled participants moderate severe active ra diseasemodifying antirheumatic drugs work well could participants least six tender six swollen joints increased levels high sensitivity creactive protein hscrp substance produced body protect trials lasted trial enrolled participants never treated participants randomly assigned receive one two doses upadacitinib methotrexate daily neither subject healthcare providers knew medication given treatment trial enrolled participants methotrexate work participants randomly assigned receive one two doses upadacitinib daily mouth continue usual dose methotrexate week participants assigned methotrexate received upadacitinib mouth neither subject healthcare providers knew medication trial enrolled participants diseasemodifying antirheumatic drugs work participants randomly assigned receive one two doses upadacitinib placebo daily mouth addition diseasemodifying antirheumatic drugs week participants received placebo reassigned upadacitinib neither subject healthcare providers knew medication trial enrolled participants methotrexate work participants randomly assigned receive upadacitinib placebo daily mouth addition methotrexate participants receiving placebo adequate improvement signs andor symptoms could switched upadacitinib week week participants receiving placebo switched upadacitinib daily neither subject healthcare providers knew medication trial enrolled participants diseasemodifying antirheumatic drugs work well could participants randomly assigned receive one two doses upadacitinib placebo treatment daily added diseasemodifying antirheumatic drugs week participants received placebo reassigned upadacitinib benefit upadacitinib measured comparing proportion participants treated upadacitinib achieved american college rheumatology response week week proportion participants treated mtx placebo achieved improvement signs symptoms upadacitinib approved medical use european union december february upadacitinib approved uk treatment crohns april upadacitinib approved eu treatment moderately severely active crohns disease approval adults inadequate response lost response intolerant conventional therapy biological efficacy safety upadacitinib evaluated two randomized induction trials participants moderately severely active crohns disease participants randomized receive mg upadacitinib placebo day week greater proportion participants treated mg upadacitinib compared placebo achieved clinical remission based crohns disease activity index cdai measures clinical laboratory variables estimate disease activity crohns similarly greater proportion participants treated mg upadacitinib demonstrated improvement intestinal inflammation assessed assess upadacitinib maintenance treatment evaluated participants responded weeks mg upadacitinib participants rerandomized receive maintenance regimen mg upadacitinib daily placebo weeks representing total least weeks week greater proportion participants treated mg mg upadacitinib compared placebo achieved clinical remission based cdai demonstrated improvement intestinal inflammation assessed safety efficacy upadacitinib evaluated multiple clinical phase study revealed upadacitinib followed biexponential disposition terminal halflife significant accumulation dose range mg per day interaction found rheumatoid arthritis participants taking methotrexate common adverse event headache incidence similar taking placebo upadacitinib vs placebo investigation absorption metabolism found dosing highfat meal effect upadacitinib total drug exposure time area curve two phase iib studies initiated study efficacy safety upadacitinib participants rheumatoid arthritis one phase ii study initiated participants crohns disease first study rheumatoid arthritis participants recruited previously experienced inadequate response necrosis factor tnf therapy currently stable dose participants randomized receive mg twice daily placebo primary endpoint improvement symptoms according american college rheumatology improvement criteria completion study found response rates significantly higher receiving upadacitinib versus receiving placebo alone respectively adverse events included headache nausea infection infections serious second phase iib study rheumatoid arthritis participants recruited inadequate response participants randomized receive mg twice daily placebo primary endpoint improvement symptoms according american college rheumatology improvement criteria completion study found response rates significantly higher receiving upadacitinib versus receiving placebo alone mg doses respectively placebo improvement symptoms rapid significant changes disease scores week adverse events mild infection serious one case communityacquired pneumonia occurred mg needs update study participants recruited moderately severely active crohns disease participants must also experienced inadequate response intolerance immunotherapy tnf participants randomized therapy upadacitinib mg twice daily mg daily weeks placebo followed blinded extension therapy weeks coprimary endpoints proportion participants achieved clinical remission soft stool frequency daily abdominal pain score week endoscopic remission week secondary endpoints included significant clinical response reduction symptoms week endoscopic response decrease symptoms week weeks participants taking mg twice daily dose achieved endoscopic remission upadacitinib compared participants taking placebo participants taking mg twice daily dose achieved clinical remission compared participants taking placebo adverse events appear doserelated single case nonmelanoma skin cancer reported mg twice daily group abbvie planned total six phase iii trials evaluate participants moderate severe rheumatoid two phase iii trials planned studying participants psoriatic arthritis one participants ulcerative colitis selectcompare participants moderate severe rheumatoid arthritis inadequate response methotrexate randomized oncedaily upadacitinib placebo adalimumab stable background methotrexate primary endpoints versus placebo week inhibition radiographic progression evaluated week study designed powered test noninferiority superiority upadacitinib versus adalimumab clinically functionally week primary endpoints met upadacitinib versus placebo achieved versus versus upadacitinib superior adalimumab δpain δhaqdi week participants upadacitinib vs placebo adalimumab achieved low disease activity remission radiographic progression less observed fewer participants receiving upadacitinib versus placebo week adverse events aes including serious infections comparable upadacitinib adalimumab proportions participants serious aes aes leading discontinuation highest adalimumab proportion herpes zoster cpk elevations highest upadacitinib three malignancies five mace four deaths reported none upadacitinib six venous thromboembolic events reported placebo one upadacitinib two adalimumab three upadacitinib superior placebo adalimumab improving signs symptoms physical function ra participants background methotrexate significantly inhibited radiographic progression versus placebo overall safety profile generally similar adalimumab except higher rates herpes zoster cpk elevations selectchoice phase iii trial comparing upadacitinib abatacept people whose rheumatoid arthritis respond biologic diseasemodifying antirheumatic drugs compared ability reduce disease activity crp crp measure rheumatoid arthritis disease severity includes number tender swollen joints creactive protein level marker inflammation overall health reported standardized scale trial found weeks treatment people treated upadacitinib lower crp scores higher rate remission also higher rate serious opportunistic infections elevated liver enzymes thromboembolism upadacitinib httpsenwikipediaorgwikiupadacitinib